Free Trial
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

Innate Pharma logo
$1.88
-0.02 (-1.06%)
(As of 11/1/2024 ET)

About Innate Pharma Stock (NASDAQ:IPHA)

Key Stats

Today's Range
$1.83
$1.91
50-Day Range
$1.71
$2.44
52-Week Range
$1.70
$3.15
Volume
6,627 shs
Average Volume
9,202 shs
Market Capitalization
$151.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Strong Buy

Company Overview

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Innate Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

IPHA MarketRank™: 

Innate Pharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 416th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innate Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Innate Pharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Innate Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Innate Pharma are expected to grow in the coming year, from ($0.98) to ($0.94) per share.

  • Price to Book Value per Share Ratio

    Innate Pharma has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.07% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 18.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 18.11%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innate Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.16% of the stock of Innate Pharma is held by institutions.

  • Read more about Innate Pharma's insider trading history.
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Leerink Partners Reaffirms Their Buy Rating on Innate Pharma (IPHA)
See More Headlines

IPHA Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $2.80 at the beginning of the year. Since then, IPHA shares have decreased by 33.0% and is now trading at $1.8750.
View the best growth stocks for 2024 here
.

Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO.

Top institutional investors of Innate Pharma include Exchange Traded Concepts LLC (0.10%).

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPHA
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$11.50
Low Stock Price Target
$11.50
Potential Upside/Downside
+513.3%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Book Value
$0.69 per share

Miscellaneous

Free Float
55,147,000
Market Cap
$151.82 million
Optionable
Not Optionable
Beta
0.39
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IPHA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners